Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. QNCX
QNCX logo

QNCX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Quince Therapeutics Inc (QNCX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.950
1 Day change
4.65%
52 Week Range
45.500
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Quince Therapeutics Inc (QNCX) is not a strong buy for a beginner investor with a long-term focus at this time. The stock lacks significant positive catalysts, has neutral trading sentiment, and no recent signals from Intellectia Proprietary Trading Signals. Additionally, technical indicators suggest a bearish trend, and there is no recent financial or valuation data to support a bullish case. A hold position is recommended until more favorable conditions emerge.

Technical Analysis

The MACD is slightly positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 44.427, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels are Pivot: 0.973, R1: 1.052, S1: 0.895, R2: 1.1, S2: 0.846. Overall, the technical outlook is bearish.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
6

Positive Catalysts

  • NULL identified. No recent news, significant insider or hedge fund activity, or congress trading data. No AI Stock Picker or SwingMax signals.

Neutral/Negative Catalysts

  • Bearish moving averages and lack of significant trading trends. Stock trend analysis suggests a 50% chance of a slight decline (-2.97%) over the next week.

Financial Performance

No financial data available for analysis. Latest quarter season could not be assessed.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available.

Wall Street analysts forecast QNCX stock price to rise
3 Analyst Rating
Wall Street analysts forecast QNCX stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.903
sliders
Low
5
Averages
7
High
10
Current: 0.903
sliders
Low
5
Averages
7
High
10
D. Boral Capital
Buy
to
Hold
downgrade
AI Analysis
2026-01-30
Reason
D. Boral Capital
Price Target
AI Analysis
2026-01-30
downgrade
Buy
to
Hold
Reason
D. Boral Capital downgraded Quince Therapeutics to Hold from Buy without a price target after the company reported negative results from its pivotal Phase 3 NEAT clinical trial in ataxia-telangiectasia. The company's core value driver has been removed, and the equity "appears fully impaired at this stage," the analyst tells investors in a research note.
Maxim
Buy
to
Hold
downgrade
2026-01-30
Reason
Maxim
Price Target
2026-01-30
downgrade
Buy
to
Hold
Reason
Maxim downgraded Quince Therapeutics to Hold from Buy.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for QNCX
Unlock Now

People Also Watch